The stock of Fate Therapeutics Inc (NASDAQ:FATE) is a huge mover today! About 74,869 shares traded hands. Fate Therapeutics Inc (NASDAQ:FATE) has risen 53.65% since March 9, 2016 and is uptrending. It has outperformed by 46.23% the S&P500.
The move comes after 8 months negative chart setup for the $94.91 million company. It was reported on Oct, 12 by Barchart.com. We have $2.38 PT which if reached, will make NASDAQ:FATE worth $13.29M less.
Analysts await Fate Therapeutics Inc (NASDAQ:FATE) to report earnings on November, 1. They expect $-0.28 earnings per share, down 16.67% or $0.04 from last year’s $-0.24 per share. After $-0.29 actual earnings per share reported by Fate Therapeutics Inc for the previous quarter, Wall Street now forecasts -3.45% EPS growth.
Fate Therapeutics Inc (NASDAQ:FATE) Ratings Coverage
Out of 5 analysts covering Fate Therapeutics (NASDAQ:FATE), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Fate Therapeutics has been the topic of 5 analyst reports since October 6, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Thursday, September 22 by Roth Capital. The rating was initiated by Raymond James with “Outperform” on Tuesday, October 6. BMO Capital Markets initiated the shares of FATE in a report on Tuesday, April 12 with “Outperform” rating. Wells Fargo initiated the stock with “Outperform” rating in Friday, December 4 report. The firm earned “Buy” rating on Thursday, September 22 by TH Capital.
According to Zacks Investment Research, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.”
Insitutional Activity: The institutional sentiment decreased to 0.56 in 2016 Q2. Its down 0.40, from 0.96 in 2016Q1. The ratio turned negative, as 7 funds sold all Fate Therapeutics Inc shares owned while 11 reduced positions. 1 funds bought stakes while 9 increased positions. They now own 13.89 million shares or 11.32% less from 15.66 million shares in 2016Q1.
Da Davidson & last reported 0% of its portfolio in the stock. Creative Planning reported 17,000 shares or 0% of all its holdings. Fmr Ltd Liability holds 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 4.31M shares. Lombard Odier Asset (Usa) Corporation, a New York-based fund reported 256,426 shares. Blackrock Fund last reported 75,572 shares in the company. Board Of Trustees Of The Leland Stanford Junior University has 0.07% invested in the company for 291,067 shares. First Manhattan accumulated 7,750 shares or 0% of the stock. Tocqueville Asset Ltd Partnership has 22,000 shares for 0% of their US portfolio. Franklin Resources last reported 0% of its portfolio in the stock. Belmont Glob Advsr owns 400,000 shares or 0.65% of their US portfolio. Jacobs Levy Equity Mgmt has 0.01% invested in the company for 178,647 shares. Vanguard Group Inc, a Pennsylvania-based fund reported 657,573 shares. Blackrock Advisors Limited Com last reported 0% of its portfolio in the stock. Morgan Stanley owns 1,030 shares or 0% of their US portfolio. Geode Capital Limited Liability Company, a Massachusetts-based fund reported 108,029 shares.
More recent Fate Therapeutics Inc (NASDAQ:FATE) news were published by: 247Wallst.com which released: “Could This Be a Turning Point for Fate Therapeutics?” on June 20, 2016. Also Globenewswire.com published the news titled: “Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch …” on September 07, 2016. Streetinsider.com‘s news article titled: “Fate Therapeutics (FATE) Issued U.S. Patent No. 9452186 Covering Enhanced …” with publication date: October 05, 2016 was also an interesting one.
FATE Company Profile
Fate Therapeutics, Inc. (Fate Therapeutics), incorporated on April 27, 2007, is a clinical-stage biopharmaceutical company. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. The Firm programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. The Company’s adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.